Cargando…

Emerging Targets in Clear Cell Renal Cell Carcinoma

SIMPLE SUMMARY: Immuno-Oncology (IO) based combinations are now the standard of care for frontline advanced clear cell renal cell carcinoma. Despite the unprecedented durable efficacy of such combinations, many patients do not respond to IO or will eventually develop resistance. This review summariz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yu-Wei, Rini, Brian I., Beckermann, Kathryn E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561986/ https://www.ncbi.nlm.nih.gov/pubmed/36230766 http://dx.doi.org/10.3390/cancers14194843

Ejemplares similares

Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications
por: Wolf, Melissa M., et al.
Publicado: (2020)

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
por: Tucker, Matthew D., et al.
Publicado: (2020)

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
por: Beckermann, Kathryn, et al.
Publicado: (2023)

The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007)

Antigenic targets in clear cell renal cell carcinoma
por: Schindler, Nicholas R., et al.
Publicado: (2023)

OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
por: Beckermann, Kathryn, et al.
Publicado: (2023)

Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma
por: Toth, Alexander T., et al.
Publicado: (2020)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Treatment of Refractory Metastatic Renal Cell Carcinoma
por: Vento, Joseph A., et al.
Publicado: (2022)

Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
por: Mehdi, Ali, et al.
Publicado: (2017)

Targeting the Deterministic Evolutionary Trajectories of Clear Cell Renal Cell Carcinoma
por: Kowalewski, Adam, et al.
Publicado: (2020)

Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2020)

Editorial: Case reports in renal cell carcinoma
por: Zhuang, Tony Z., et al.
Publicado: (2023)

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
por: Xu, Kevin Y, et al.
Publicado: (2015)

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
por: Ged, Yasser, et al.
Publicado: (2020)

Orellanine specifically targets renal clear cell carcinoma
por: Buvall, Lisa, et al.
Publicado: (2017)

The epigenetic landscape of clear-cell renal cell carcinoma
por: Kluzek, Katarzyna, et al.
Publicado: (2015)

MBOAT7-driven phosphatidylinositol remodeling promotes the progression of clear cell renal carcinoma
por: Neumann, Chase K.A., et al.
Publicado: (2020)

Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies
por: Schiavoni, Valentina, et al.
Publicado: (2023)

Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma
por: Bobulescu, Ion Alexandru, et al.
Publicado: (2021)

The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma
por: Oxburgh, Leif
Publicado: (2022)

Clear Cell Renal Cell Carcinoma: From Biology to Treatment
por: Kase, Adam M., et al.
Publicado: (2023)

The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma
por: Monjaras-Avila, Cesar U., et al.
Publicado: (2023)

Combination drug regimens for metastatic clear cell renal cell carcinoma
por: Khetani, Viraj V, et al.
Publicado: (2020)

Diagnostic and Prognostic Biomarkers in Renal Clear Cell Carcinoma
por: Weaver, Chaston, et al.
Publicado: (2022)

Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing
por: Lin, Po-Hung, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
por: Aeppli, Stefanie, et al.
Publicado: (2020)

miRNAs in Prediction of Prognosis in Clear Cell Renal Cell Carcinoma
por: Ran, LongJiao, et al.
Publicado: (2017)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Molecular and Metabolic Subtypes in Sporadic and Inherited Clear Cell Renal Cell Carcinoma
por: Czyzyk-Krzeska, Maria F., et al.
Publicado: (2021)

Spatial proteomics enables identification of prognostic biomarkers in papillary renal cell carcinoma
por: Haake, Scott, et al.
Publicado: (2023)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
por: Vecchio, Sharon J. Del, et al.
Publicado: (2018)

Paraneoplastic Eosinophilia in Clear Cell Renal Cell Carcinoma
por: Zhou, Wei-Wei, et al.
Publicado: (2015)

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
por: Chatwal, Monica Sheila, et al.
Publicado: (2023)

The target therapy of ovarian clear cell carcinoma
por: Jin, Ying, et al.
Publicado: (2014)

The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma
por: Berg, Stephanie A., et al.
Publicado: (2022)

Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma
por: Sepe, Pierangela, et al.
Publicado: (2021)

Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC)
por: Rysz, Jacek, et al.
Publicado: (2021)

Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma
por: Pezzicoli, Gaetano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_67vli2pjiqu0i4t2rntavgpvk9